Physiologic and clinical relevance of the insulin-like growth factor binding proteins

P. Cohen, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The insulin-like growth factors (IGFs) are potent mitogenic agents that have been recognized for three decades. Recently, however, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific receptors that bind IGFs and mediate their biologic actions have been characterized. A family of six peptides, which bind IGFs with high affinity, the IGF binding proteins (IGFBPs), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance IGF actions, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by a group of proteolytic enzymes, which are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The size IGFBPs, although similar, have unique biologic properties, and appear to have specific patterns of expression and function. Radioimmunoassay for IGFBP-1, -2, and -3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin-secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

Original languageEnglish (US)
Pages (from-to)462-467
Number of pages6
JournalCurrent Opinion in Pediatrics
Volume6
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Somatomedins
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 1
Blood Proteins
Growth Disorders
Somatomedin Receptors
Insulin-Like Growth Factor Binding Protein 3
Carbohydrate Metabolism
Growth Hormone
Radioimmunoassay
Peptide Hydrolases
Cell Membrane
Insulin
Peptides
Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Physiologic and clinical relevance of the insulin-like growth factor binding proteins. / Cohen, P.; Rosenfeld, Ronald (Ron).

In: Current Opinion in Pediatrics, Vol. 6, No. 4, 1994, p. 462-467.

Research output: Contribution to journalArticle

Cohen, P. ; Rosenfeld, Ronald (Ron). / Physiologic and clinical relevance of the insulin-like growth factor binding proteins. In: Current Opinion in Pediatrics. 1994 ; Vol. 6, No. 4. pp. 462-467.
@article{4c47f38ac8c9476380ffb4cbfde10506,
title = "Physiologic and clinical relevance of the insulin-like growth factor binding proteins",
abstract = "The insulin-like growth factors (IGFs) are potent mitogenic agents that have been recognized for three decades. Recently, however, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific receptors that bind IGFs and mediate their biologic actions have been characterized. A family of six peptides, which bind IGFs with high affinity, the IGF binding proteins (IGFBPs), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance IGF actions, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by a group of proteolytic enzymes, which are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The size IGFBPs, although similar, have unique biologic properties, and appear to have specific patterns of expression and function. Radioimmunoassay for IGFBP-1, -2, and -3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin-secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.",
author = "P. Cohen and Rosenfeld, {Ronald (Ron)}",
year = "1994",
language = "English (US)",
volume = "6",
pages = "462--467",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Physiologic and clinical relevance of the insulin-like growth factor binding proteins

AU - Cohen, P.

AU - Rosenfeld, Ronald (Ron)

PY - 1994

Y1 - 1994

N2 - The insulin-like growth factors (IGFs) are potent mitogenic agents that have been recognized for three decades. Recently, however, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific receptors that bind IGFs and mediate their biologic actions have been characterized. A family of six peptides, which bind IGFs with high affinity, the IGF binding proteins (IGFBPs), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance IGF actions, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by a group of proteolytic enzymes, which are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The size IGFBPs, although similar, have unique biologic properties, and appear to have specific patterns of expression and function. Radioimmunoassay for IGFBP-1, -2, and -3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin-secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

AB - The insulin-like growth factors (IGFs) are potent mitogenic agents that have been recognized for three decades. Recently, however, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific receptors that bind IGFs and mediate their biologic actions have been characterized. A family of six peptides, which bind IGFs with high affinity, the IGF binding proteins (IGFBPs), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance IGF actions, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by a group of proteolytic enzymes, which are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The size IGFBPs, although similar, have unique biologic properties, and appear to have specific patterns of expression and function. Radioimmunoassay for IGFBP-1, -2, and -3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin-secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

UR - http://www.scopus.com/inward/record.url?scp=0028145165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028145165&partnerID=8YFLogxK

M3 - Article

C2 - 7951670

AN - SCOPUS:0028145165

VL - 6

SP - 462

EP - 467

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 4

ER -